Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by MHemorrhageon Apr 14, 2021 12:00pm
76 Views
Post# 32993043

RE:Something to keep in mind

RE:Something to keep in mindAlso chiming in here to say the lockdowns this winter in Canada especially were even more significant than last year. I've been trading cannabis stocks for years and sales took a hit this last Q when they didn't throughout 2020

juniper88 wrote: First of all, I don't believe the sales of the legacy medicines is where the value is for Thera.

That said, traditionally Q1 sales are somewhat weak and it is hard to compare to the last Q4.  

And comparing this year's Q1 to last year's Q1 you need to keep in mind that covid-19 hardly would have affected last year's sales (any lock downs as of Feb 28, 2020?), while this year's Q1 probably was the worst part of the pandemic so far.  It probably affected sales.


<< Previous
Bullboard Posts
Next >>